Search results
Results from the WOW.Com Content Network
After eight weeks of phage therapy, in conjunction with 12 weeks of antibiotics, no evidence of Acinetobacter baumannii was found in Patterson's body following June 6, 2016. [ 5 ] [ 8 ] After positive media attention from Patterson's phage therapy, [ 9 ] [ 10 ] [ 11 ] Schooley and Strathdee began to receive phage therapy requests from around ...
Phage therapy, viral phage therapy, or phagotherapy is the therapeutic use of bacteriophages for the treatment of pathogenic bacterial infections. [1] [2] [3] This therapeutic approach emerged at the beginning of the 20th century but was progressively replaced by the use of antibiotics in most parts of the world after the Second World War.
Phage therapy also allows for the possibility of biofilm penetration in cases where antibiotics are ineffective due to the increased resistance of biofilm-forming pathogens. [9] One major drawback to phage therapy is the evolution of phage-resistant microbes which was seen in a majority of phage therapy experiments aimed to treat sepsis and ...
This problem prompted researchers to look towards other possible regulators of bacterial growth, like Autographiviridae bacteriophages. [5] This type of treatment is referred to as phage therapy. Phage therapy is effective against drug-resistant bacteria because bacteriophages are naturally inclined to infect and kill specific bacteria. [7]
The 'Nuts and Bolts' of Phage Therapy. a special issue of the journal, Current Pharmaceutical Biotechnology, consisting of six articles on phage therapy, plus an editorial. Carnazza, S., Guglielmino, S. eds. 2010. Phage Display As a Tool for Synthetic Biology. Nova Science Publishers, Hauppauge, New York. ISBN 978-1-60876-987-2, Google Books
Mycobacteriophage Bxb1 Structure [1]. A mycobacteriophage is a member of a group of bacteriophages known to have mycobacteria as host bacterial species. While originally isolated from the bacterial species Mycobacterium smegmatis and Mycobacterium tuberculosis, [2] the causative agent of tuberculosis, more than 4,200 mycobacteriophage species have since been isolated from various environmental ...
Robert "Chip" T. Schooley (born November 10, 1949) is an American infectious disease physician, who is the Vice Chair of Academic Affairs, Senior Director of International Initiatives, and Co-Director at the Center for Innovative Phage Applications and Therapeutics (IPATH), at the University of California San Diego School of Medicine.
The George Eliava Institute of Bacteriophage, Microbiology and Virology [1] (aka Tbilisi Institute) has been active since the 1930s in the field of phage therapy, which is used to combat microbial infection (cf. antibiotic-resistant strains).